A Prospective Observational Study Of Erivedge Treatment, Effectiveness, and Safety Outcomes In Patients With Advanced Basal Cell Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Basal cell nevus syndrome
- Focus Therapeutic Use
- Sponsors Roche
- 01 Jul 2016 Planned number of patients changed from 50 to 40.
- 01 Jul 2016 Planned End Date changed from 1 Mar 2020 to 1 Dec 2019.
- 01 Jul 2016 Planned primary completion date changed from 1 Mar 2020 to 1 Dec 2019.